Article
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
International journal of clinical oncology - 1 Oct 2017
Shiseki Masayuki, Yoshida Chikashi, Takezako Naoki, Ohwada Akira, Kumagai Takashi, Nishiwaki Kaichi, Horikoshi Akira, Fukuda Tetsuya, Takano Hina, Kouzai Yasuji, Tanaka Junji, Morita Satoshi, Sakamoto Junichi, Sakamaki Hisashi, Inokuchi Koiti
Abstract excerpt
BACKGROUND: With the introduction of imatinib, a first-generation tyrosine kinase inhibitor (TKI) to inhibit BCR-ABL1 kinase, the outcome of chronic-phase chronic myeloid leukemia (CP-CML) has improved dramatically. However, only a small proportion of CP-CML patients subsequently achieve a deep molecular response (DMR) with imatinib. Dasatinib, a second-generation TKI, is more potent than imatinib in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.